Activation of the PI3K/Akt signaling pathway is one the most frequent genetic events in human cancer. A cell-based imaging assay that monitored the translocation of the Akt effector protein, FOXO, from the cytoplasm to the nucleus was employed to screen a collection of 33,992 small molecules. The positive compounds were used to screen kinases known to be involved in FOXO translocation. Pyrazolopyrimidine derivatives were found to be potent FOXO relocators as well as biochemical inhibitors of PI3K A combination of virtual screening and molecular modelling lead to the development of a structure activity relationship which indicated the preferred substituents on the pyrazolopyrimidine scaffold. This lead to the synthesis of ETP-45658 which is a potent and selective inhibitor of phosphoinositide 3-kinases and demonstrates mechanism of action in tumor cell lines and in vivo in treated mice.
Activation of the PI3K/Akt signaling pathway is one the most frequent genetic events in human cancer. A cell-based imaging assay that monitored the translocation of the Akt effector protein, FOXO, from the cytoplasm to the nucleus was employed to screen a collection of 33,992 small molecules. The positive compounds were used to screen kinases known to be involved in FOXO translocation. Pyrazolopyrimidine derivatives were found to be potent FOXO relocators as well as biochemical inhibitors of PI3K A combination of virtual screening and molecular modelling lead to the development of a structure activity relationship which indicated the preferred substituents on the pyrazolopyrimidine scaffold. This lead to the synthesis of ETP-45658 which is a potent and selective inhibitor of phosphoinositide 3-kinases and demonstrates mechanism of action in tumor cell lines and in vivo in treated mice.
The phosphoinositide-3-kinase (PI3K)/Akt pathway is activated in a variety of solid and non-solid tumors (1) and therefore is considered as a potential invention point for anti-cancer therapeutics. Activation of the pathway is frequently caused by mutations in PI3Kthat enhance its catalytic activity, leading to the generation of phosphatidyl, 3, 4, 5-triphosphate (PIP3) (2) or by mutations or deletions in the tumor suppressor PTEN (phosphatase and tensin homolog) that result in its loss of function. PTEN antagonizes the activity of PI3K through the dephosphorylation PIP3 (3). In addition, PI3K can be activated by mutations in certain receptor tyrosine kinases as well as by mutations in the oncogene KRAS (4, 5) . The PIP3 generated by activation of PI3K or sustained by the inactivation of PTEN binds to a subset of lipid-binding domains in downstream targets such as the pleckstrin homology (PH) domain of the oncogene Akt (6,7) thereby recruiting it to the plasma membrane. Once at the plasma membrane Akt can be activated (8, 9) . When active, Akt phosphorylates several effector molecules including the Forkhead box O (FOXO) transcription factors (10, 11) . The FOXO proteins are a family of conserved polypeptides that bind to DNA as a monomer and activate the transcription of genes that are involved in numerous biologically relevant processes such as metabolism, differentiation, proliferation, longevity and apoptosis (12, 13) . Akt phosphorylates FOXO proteins at three conserved consensus sites, which leads to conformational changes that facilitate CRM-1-mediated nuclear export (14, 15) . Nuclear FOXO proteins function as regulators of transcription whereas cytoplasmic FOXO proteins are considered inactive. It is well established that FOXO is negatively regulated by various proliferative and anti-apoptotic signaling pathways that activate the PI3K/Akt signaling cascade (11) . Therefore we chose to employ a high content imaging approach to monitor the nucleo-cytoplasmic translocation of a GFPFOXO3a fusion protein in U2OS cells (U2foxRELOC) (16, 17) as the readout for biological inhibition of PI3K/Akt signaling. The rapid kinetics of the assay allowed us to reduce the incubation time and minimize possible toxic effects that might interfere with the analysis. Furthermore this image based high throughput strategy provides a filter for adequate solubility, permeability and stability in a cellular context and enables compounds that produce artifacts or cytotoxicity to be identified on a single cell basis. Often a key limitation of cell-based screening approaches is the identification of the compound's molecular target. For this reason the cell-based screen was followed by focused screen of kinases thought to be involved in the regulation of the intracellular localization of FOXO proteins. This screen identified pyrazolopyrimidine derivatives as inhibitors of PI3K. Finally a combination of computational and synthetic medicinal chemistry was used to optimize the chemical features required for activity. Here we report the discovery of a novel series of PI3K inhibitors discovered by cellular high content screening that are potent, selective and demonstrate mechanism of action in vivo.
Materials and Methods
Compounds. Compounds were purchased from ChemDiv (San Diego, CA), BioFocus (Cambridge, UK), and Life Chemicals (Burlington, Canada). LY294002 was from Calbiochem (San Diego, CA). Leptomycin B was purchased from LC Laboratories (Woburn, MA, U.S .A.).
Different but complementary criteria were considered for compounds selection and purchase: a) chemistry perspective: druglike compounds and b) biological point of view: structures focused on kinases (kinases libraries) as well as a diverse set of compounds -exploring different chemical space with a potential biological activity.
Compounds were purchased from ChemDiv and Life Chemicals. Their structure and purity (>90 %) have been validated by NMR and/or LCMS. The compounds that have been synthesized in house are at least 95% pure by LCMS and NMR (see supplementary information for details). Plasmids. The GFP-FOXO3a fusion protein was kindly provided by T. Finkel. The U2nesRELOC assay uses the reporter construct pRev MAPKKnes GFP which has been described earlier (18, 19) . pRev MAPKKnes GFP carries the nuclear export signal from MAPKK cloned between the BamHI and AgeI sites of pRev(1.4)-GFP, sandwiched between the Rev and the GFP coding sequences. Cell culture. The cell lines were obtained from the American Type Culture Collection (ATTC). U2OS (human osteosarcoma) was cultured in Dulbecco's modified Eagle's medium (DMEM). PC3 (human prostate carcinoma), MCF7 (human breast carcinoma), HCT116 (human colon carcinoma), 768-0 (human renal carcinoma), U251 (human glioblastoma) were grown in RPMI. All media were supplemented with 10% fetal bovine serum (Sigma) and antibiotics-antimycotics. Cell were maintained in a humidified incubator at 37°C with 5% CO 2 and passaged when confluent using trypsin/EDTA. U2foxRELOC and U2nesRELOC assay. The U2nesRELOC assay and the U2foxRELOC assay have been described previously (16, 19) . Briefly, cells were seeded at a density of 1.0×10 5 cells/ml into black-wall clear-bottom 96-well microplates (BD Biosciences) after 12 hours incubation at 37°C with 5% CO 2 , 2 l of each test compound were transferred from the mother plates to the assay plates. Cells were incubated in the presence of the compounds for one hour. Then cells were fixed and the nucleus stained with DAPI (Invitrogen). Finally the plates were washed with 1X PBS twice and stored at 4ºC before analysis. Kinase Assays. Detailed methods are described as supplementary information. Docking. Gold 3.1 programme (21) was used to carry out docking of LY294002, PI-103 and ETP-45658 to p110 with the crystal structure of p110 complexed with staurosporine pdb entry 1e8z (20) . The binding site was defined using the available experimental information; thus, the docking region used was a 15-Å sphere around the nitrogen NH of Val882 GoldScore scoring function was used to rank docking poses and protein hydrogen bond constraint for binding to NH of Val882 was imposed on the ligand. Per each ligand, the top five best docked structures out of 40 independent genetic algorithm runs were retrieved. For validation purposes, we compared the data for LY294002 and PI-103 docked to p110 with the corresponding crystal structure of p110 for LY294002 pdb entry 1e7v (20) and the proposed binding mode for PI-103 as described by Knight et al (21) . Besides qualitative assessment, key interactions properly identified, Root Mean Square Deviation (RMSD) is utilized as quantitative validation criteria for docking algorithm set-up; thus, RMSD between experimentally reported LY294002 and the best predicted pose are 2.3 A (1e8z, cross-docked structure) and 1.5 A when own crystal for LY294002 (1e7v) is used. For PI-103, only docking using 1e8z yielded a reliable binding mode similar to the one described by Knight et al. (21) , in which the morpholine oxygen was seen to form a hydrogen bond to Val882 and the phenol group is oriented into the hydrophobic cavity, qualitative comparison. By superimposing 1e7v and 1e8z structures, we observed that the side chain of Lys833 is more extended than in 1e8z, entering into the cavity occupied by the phenol group of PI-103 in the binding mode obtained with 1e8z. We have hypothesized that this extended conformation of the side chain of Lys833 underlies the docking failure of PI-103 in 1e7v crystal. Based on this validation results, 1e8z crystal was finally selected as protein structure for docking of ETP-45658.
RESULTS

Identification of FOXO Relocators
The strategy used to identify biologically active inhibitors of PI3K/Akt signaling is outlined in figure 1A . As the primary filter we used a cellular imaging assay that follows the intracellular location of FOXO proteins (16) . U2OS osteosarcoma cells that stably express a green fluorescent protein (GFP)-tagged version of FOXO3a were seeded in 96-well assay plates and treated with compounds at a final concentration of 10M for 1 hour. A total of 33,992 compounds were screened for their ability to induce the translocation the GFPFOXO3a reporter protein from the cytoplasm into the nucleus. The nuclear accumulation of fluorescence triggered by the pan-PI3K inhibitor, LY294002, was defined as 100% activity and used as a reference. Primary hits were defined as those compounds that have an activity greater than 60%. After retesting 242 compounds were confirmed as positive yielding a hit rate of 0.71%. A sample image of an active compound is shown in Figure 1B (upper right). In order to exclude compounds that could be general inhibitors of the nuclear export machinery rather than selective inducers of FOXO nuclear translocation, the ability of the compounds to influence the localization of a Nuclear Export Signal (NES)-containing fluorescent reporter protein (19) was determined. Briefly, the nuclear export assay uses U2OS cells that stably express a GFP labelled Rev protein which contains a strong heterologous NES sequence. The fluorescent signal of untreated cells localizes exclusively to the cytoplasm. Upon treatment with a nuclear export inhibitor such as leptomycin B the GFPlabeled reporter protein accumulates rapidly in the cell nucleus ( Figure Figure 1B , middle right). Fourteen of the original 242 confirmed hits induced the nuclear localization of Rev protein and were classified as nonspecific inhibitors as inhibitors of the Crml-dependent nuclear export, an example of a positive compound is shown in the lower right panel of Figure 1B . The remaining 228 confirmed positives in the FOXO translocation assay and that were negative ( Figure 1b , lower left panel) in the nuclear export assay were classified as FOXO relocators. The FOXO relocators were then screened against protein kinases that are known to phosphorylate FOXO3a at sites involved in the regulation of its intracellular localization either directly, such as Akt1-3, Sgk 1-3 or indirectly by activating Akt, such as PI3K and PDK1 (10, 22) . No inhibitors of PDK1, Akt1-3, or Sgk1-3 were identified. However, 54 compounds representing 24 distinct chemical classes, six of which had two or more representatives, were identified as biochemical inhibitors of PI3Kα. Of the remaining 174 FOXO relocators, which were not inhibitors of PI3K 155 were screened against an extended panel of protein kinases that have been implicated in signaling networks that regulate FOXO proteins ( Supplementary Information, Figure S1 ). Five compounds non-specifically inhibited several receptor tyrosine kinases (RTKs) while no other significant inhibitory activity was observed. In summary, a total of the 242 FOXO relocators identified; 6 % were nonspecific inhibitors of nuclear export, 21% were inhibitors of PI3K 2% were nonspecific inhibitors of RTKs and 71 % were classified as inhibitors of an unknown target(s).
Pyrazolopyrimidines as Inhibitors of PI3K
Pyrazolopyrimidine derivatives were the most potent biochemical inhibitors of PI3K identified from the primary screen ( Figure 2 ). The pyrazolopyrimidines had IC 50 's for inhibition of PI3K ranging from 0.4 to 12 M (Figure 2a ). In addition they induced a clear nuclear FOXO translocation EC 50 values between 0.54 to 26.6 M ( Figure 2A ). As expected, the compounds inhibited Akt phosphorylation at serine 473 in treated cells ( Figure 2B ). The pyrazolopyrimidine, ETP-7382, was the most potent biochemical inhibitor of PI3K and the most potent inducer of FOXO nuclear translocation obtained from the primary screen ( Figure 2A ). Therefore this compound was selected for further mechanism of action studies. Inhibition of signaling downstream of Akt was observed in cells treated with ETP-7382; both the Akt-dependent phosphorylation of FOXO3a on threonine 32 and mTOR dependent phosphorylation of p70 S6K on threonine 389 was reduced ( Figure 2C ). These observations confirmed the mechanism of action of ETP-7382 as an inhibitor of PI3K-dependent signaling. Based upon these data the pyrazolopyrimidines were selected for further investigation.
Optimization of Pyrazolopyrimidines
In order to gain insights into the structural features of pyrazolopyrimidines required to inhibit the PI3Kand maintain cellular activity we pursued a combination of virtual screening and synthetic medicinal chemistry. In the first step a Bayesian model (Supplementary Materials and Methods) was built based upon two-dimensional (2D) descriptors of structures of the confirmed positives and negatives using the data obtained from the primary FOXO relocation screen and from PI3K biochemical assay. Then, a virtual screen against a our electronic, proprietary compound collection, database of approximately 1.5 million commercially available compounds was performed using the model. This was followed by additional sub-structural searches, using as references the chemotypes represented by the initial hits with PI3K inhibitory activity. These data lead to the acquisition of 216 pyrazolopyrimidines.
Twenty of these compounds were confirmed as inducers of FOXO relocation and 18 of these also were biochemical inhibitors of PI3K yielding a hit rate of 8.33% (Supplementary Information  Table S1 ). Analysis of these data indicated that an aromatic ring played an important role as R1 or R4.
Molecular docking studies supported the hypothesis that morpholine could play a key role in either the R1 or the R4 position. The crystal structure of PI3K (23) in complex with the reference compounds LY294002 (20) and PI-103 (21) ( Figure 3A) indicates that the morpholine oxygen appears to act as a driving force to maintain a key interaction with Val882 in the hinge region (21) . Therefore the synthetic chemistry plan used morpholine as one of the key substituents for the diversity points R1 and R4, as described in Table 1 . The data presented in table 1 suggested that an aryl ring with hydrogen bond donor/acceptor moieties in the meta positions were preferred, and in particular meta-phenol, as suggested by the structural similarity to the PI3K inhibitor PI-103 (Fig. 3a) . This SAR driven rational design was further confirmed by data from Folkes et al. (24) . ETP-45658 which contains both a morpholine and meta phenol moiety (Table I ) was found to be a potent inhibitor of PI3K with an IC 50 of 22 nM ( Figure 3B ). The compound was predicted to interact with PI3K in a manner similar to LY294002 and PI-103 where the main driving forces to bind in the ATP pocket are interactions with Val882 and Tyr867 (Fig. 3A) . The mutant PI3K proteins, H1047K and K545E, that are found in human tumors, showed similar sensitivity toward ETP-45658 as the wild-type PI3Kprotein (Figure 3b ). ETP-45658 was also tested for its ability to inhibit PI3K, PI3Kand PI3K. ETP-45658 was essentially equipotent towards PI3K, IC 50 30 nM, and slightly less potent towards PI3K, IC 50 129 nM. However it had significantly less inhibitory activity toward PI3K with an IC 50 of 710 nM.
ETP-45658 had modest, but significant activity towards the class IV PI3 related kinase mTOR and DNA PK with an IC 50 's of 152 nM 70.6 nM , respectively ( Figure  3B ). ETP-45658 was further profiled against a panel of 72 protein kinases (Supplementary Information Table SII); of these kinases only focal adhesion kinase (FAK) and B-Raf were inhibited more than 35% at a concentration of 10 M (Supplementary Information Table SII) . Thus it appears that ETP-45658 is relatively selective towards phosphoinositide 3-kinases.
Mechanism of Action of ETP-45658
ETP-45658 was a potent inducer of GFP-FOXO nuclear translocation with an EC 50 of 45 nM ( Figure 4A and Supplementary Information Figure S2A ). The compound provoked a dose- Figure S2B ). The ability of ETP-45658 to impact the phosphorylation of the Akt substrates FOXO3a and Gsk3- was also examined. Consistent with the decrease in Akt phosphorylation observed above, ETP-45658 caused a 95% decrease in the phosphorylation of FOXO3a at threonine 32 and a 55% reduction on Gsk3-at serine ( Figure   4B ), both Akt substrates. It is not clear why the inhibition of the phosphorylation of FOXO3a on threonine 32 was greater than of GSK3- on serine 9 with both LY294002 and ETP-45658, perhaps the half-life of the phosphate on serine 9 of GSK3- is longer and therefore longer incubation times with the inhibitor would be required to see complete inhibition. In addition, the phosphorylation of the mTOR substrate p70 S6K was similarly reduced ( Figure 4B ). Whether this was due to the inhibition of PI3K by ETP-45658 or by ETP-45658's activity towards mTOR was not be determined. ETP-45658 treatment of cells did not alter the phosphorylation status of p42/45 ERK kinases ( Figure 4B ) indicative of cellular selectivity for the PI3K pathway. ETP-45658 also decreased the expression of cyclin D1 after one hour of treatment (Supplementary Information Figure S2C ). Consistent with this observation the cell cycle analysis of PC3 cells treated for 24 hours with ETP-45658 revealed a clear G1 arrest with no significant evidence apoptosis as indicated by the lack of a sub-G1 population of cells (Supplementary Information Figure S2D ). These data confirm that ETP-45658 efficiently inhibits PI3K signaling in treated tumor cells. The anti-proliferative activity of ETP-45658 was examined using a small panel of human cancer cell lines with either activating mutations in PI3K or loss of function of the negative regulator of PI3K, PTEN. The cellular EC 50 values for inhibition of proliferation were found to be between 0.4 and 5.5 M (Supplementary  Information Table SIII ). There was no obvious difference in potency towards cell lines with activating mutations in PI3K or inactivating mutations in PTEN. Since our ultimate aim is to explore the feasibility of PI3K/Akt pathway inhibitors as a cancer therapy, the pharmacological activity of ETP-45658 in vivo was examined. ETP-45658 was injected in MMTV-myr-p110 transgenic females. These transgenic lines express myristylated p110 under control of the MMTV promoter which leads to strong PI3K activation in the mammary ducts of female mice (25) . The female mice were injected with ETP-45658 or vehicle alone into transgenic littermates. As a positive control, a third cohort of mice was injected with the reference compound PI-103. Sixteen hours after treatment the mice were sacrificed and mammary glands were processed for immunohistochemistry. The epithelial-specific signal was quantified, and values of intensity of the immunohistochemical images of compound-treated mammary glands were compared with the values of the respective vehicle control images. As shown in Figure 4C the level of phosphorylated Akt on serine 473 was noticeably lower in the mammary ducts of transgenic mice injected with ETP-45658 as compared to the vehicle-treated mice. The phosphorylation of Akt was decreased to 50% of the control level (P = 0.001). The phosphorylation status of p70S6K on theonine 389 and eIF4G on serine 1108 were also examined. In all cases a clear reduction of the levels of phosphorylation was observed ( Figure  4c ). Treatment with ETP-45658 induced a significant reduction in the phosphorylation in the markers tested ( Figure. 4C ). These results confirm that ETP-45658 inhibits PI3K signaling in vivo. DISCUSSION Due to the high frequency of genetic alterations in the PI3K/Akt signalling cascade in many types of human cancer there is intense interest to discover inhibitors of this pathway in order to evaluate them as a therapeutic treatment. The research presented in this manuscript describes the use of a combination of high content cellbased screening and focused biochemical profiling of selected protein kinases to identify the molecular target of compounds with the desired mechanism of action.
This was followed by molecular modelling and traditional medicinal chemistry that led to the discovery of ETP-45658 a potent and selective inhibitor of PI3 kinases. The primary screen of 33,992 compounds followed the intracellular location of the Akt effector, FOXO3a, in tumor cells (16) . Compounds found that induced the nuclear translocation of GFP-FOXO yet did not affect general nuclear export were profiled against a small panel of protein kinases involved in the regulation of FOXO nuclear localization. This identified pyrazolopyrimidine derivatives as inhibitors of PI3K. To our surprise we did not find any inhibitors of PDK1, Akt 1-3, or SGK1-3. This is perhaps due to an unintended bias of our compound collection against targeting the AGC family of protein kinases or the possibility that the inhibitors of AGC kinases that are present in our compound collection were unable to penetrate the cell membrane and therefore could not be selected as actives in the primary cell-based screen. As we have not performed any biochemical screens vs. AGC kinase using our compound collection we cannot be sure which explanation is more accurate. A total of 174 FOXO relocators were identified that apparently had no inhibitory activity towards protein kinases that directly phosphorylates FOXO or selected upstream kinases that regulate these kinases suggesting that these compounds perhaps target proteins outside of the canonical PI3K/Akt phosphorylation cascade. Several compounds were found to be non-selective inhibitors of several receptor tyrosine kinases which could account for their activity in the FOXO assay. Kau et al. (26) reported results in a similar screen for inhibitors of FOXO1a nuclear export. No common compounds were obtained between the two screens; however three common chemical classes were found (Supplementary Figure S3A) , none of which were active towards PI3K. Chemotype 1 (C1) were phenotiazines which have been reported as ligands for monoaminerergic GPCR, dopamine receptor antogonists (27) . The second chemotype (C2) is based on four fused rings and has been reported as reversible inhibitors of monoamine oxidase (MAO) type A (28). Chemotype 3, aminoquinazolines, has been reported as protein kinase inhibitors (29) . The most frequent chemotype, C1, was present in eleven of the FOXO relocators where key chemical and pharmacophoric features, were clearly identified. An additional seven FOXO relocators were found to have the same pharmacophore yet were different chemotypes (C2 and C3). Using a high-throughput, cell-based assay to screen for modulators of the mTOR signaling network Yang et al. (30) identified quinostatin as an inhibitor of S6 phosphorylation, which they subsequently found to be a weak inhibitor of PI3K. Interestingly a derivative of quinostatin was identified in the image based screen used in the present work and biochemically inhibited PI3K ( Figure S3b) . A structure activity relationship (SAR) was developed for the pyrazolopyrimidines using the FOXO nuclear localization data coupled with the PI3K biochemical inhibitory data. The SAR analysis indicates that morpholine and substituted aryls with donor/acceptor functionalities are the preferred substituents in positions R1 and R4 of the pyrazolopyrimidine scaffold. The most active analog synthesized, ETP-45658, combines morpholine in the R1 position and meta-phenol in the R4 position of the pyrazolopyrimidine scaffold. It is an ATP competitive inhibitor of PI3K with an IC 50 of 22 nM. It is equally potent towards PI3K and PI3K as well as towards two mutant forms of PI3K that are commonly found in human tumors. The compound also inhibits PI3K, mTOR and DNA PK at sub-micromolar concentrations. Our docking studies predict that like the reference compound LY294002, ETP-45658 makes a key hydrogen bond between the oxygen in the morpholine ring and the backbone amide of V882 in p110 which mimics the interaction made by the adenine ring nitrogen (N1) of ATP (20) , in fact, a recent report (24) also describes identical interaction between Val882 and morpholine, experimentally validated, highlighting its key role. ETP-45658, PI-103 (21) and ZSTK474 (31) share LY294002's arylmorpholine structure and are potent pan-PI3K inhibitors. BEZ235, another potent pan PI3K inhibitor, also keeps the interaction with Val882 through the aromatic nitrogen born by the tricyclic central core that acts as hydrogen bond acceptor (31) . ZSTK474 inhibits all class I PI3Ks (IC 50 =16-49 nM) (32) . PI-103 inhibits PI3K (IC 50 =11 nM) as well as mTORC1/2 (IC 50 =2/83 nM, respectively (33) . ETP-45658 is mainly a pan Class I PI3K inhibitor with modest mTOR inhibitory activity. ETP-45658 elicits the expected mechanism of action in vitro and in vivo; there is a decrease in the phosphorylation of Akt at serine 473, of FOXO at theonine 32 and of p70S6K at threonine 389 in cells after treatment with the compound. The EC 50 for induction of the nuclear translocation of GFP FOXO of 45 nM consistent with the IC 50 of 22 nM obtained for biochemical inhibition of PI3K. ETP-45658 induces a G1 arrest concomitant with cyclin D1 decrease in treated cells. The compound has antiproliferative activity in a variety of tumor derived cell lines and this activity appears to be independent of PI3K and PTEN mutational status since we obtain similar results in cells with mutant PI3K and wild-type PTEN (MCF7 or HCT116) or cells with wild type PI3K and mutant PTEN (786-0, PC3 or U251). Similar observations have been reported for other PI3K inhibitors (34) . ETP-45658 is pharmacologically active in vivo. The treatment of mice that express a myristilated p110α PI 3-K subunit in mammary ductal cells with the compound caused the expected changes in selected molecular markers of pathway inhibition, including Akt, eIF4G and p70 S6K. Work continues to further optimize the pyrazolopyrimidines in order to propose a compound suitable for clinical exploration. The phosphorylation sites detected are as follows: P-Akt (serine 473), P-eIF4G (serine 1108), Pp70/S6K (threonine 389). The epithelial-specific signal was quantified, and values of intensity of the immunohistochemical images of compound-treated mammary glands were compared with the values of the respective vehicle control images. Legend: *** (P < 0.001). 
